Patent intelligence · US
US 12115163
Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor
Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor
Patent details — US 12115163
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 15, 2024
- Expiration
- Oct 10, 2044
- Applicant
- IDEAYA Biosciences, Inc.
- Claims
- 17
- CPC classes
- A61K, A61K31/495, A61K31/502, A61K31/519
Quick answer
US 12115163 (Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor) is held by IDEAYA Biosciences, Inc.. Status: granted. Granted Oct 15, 2024. Expires Oct 10, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- IDEAYA Biosciences, Inc.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/495, A61K31/502, A61K31/519, A61K45/06, A61P
More from IDEAYA Biosciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12398131
Thiadiazolyl derivatives as DNA polymerase theta inhibitors and uses thereof
granted -
US 12269820
Piperazine substituted indazole compounds as inhibitors of PARG
granted -
US 12258354
AhR modulators
granted -
US 11584755
Dihydrothieno[3,2-b]pyridine compounds
granted -
US 11548867
Amido compounds as AhR modulators
granted -
US 11530220
Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR
granted -
US 11407764
AhR modulators
granted
Frequently asked questions
What is US patent 12115163?
US 12115163 (Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor) is held by IDEAYA Biosciences, Inc.. Status: granted. Granted Oct 15, 2024. Expires Oct 10, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12115163?
IDEAYA Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 12115163 expire?
Our index shows an expiration date of Oct 10, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.